NCI-funded study evaluating Fibralign’s BioBridge® as an adjunct to microsurgical treatment SAN FRANCISCO, June 10, 2021 /PRNewswire/ -- The UCSF Rosenman Institute is proud to announce the 2021 cohort of the Rosenman Innovators, a group of early-stage health...
NCI-funded study evaluating Fibralign’s BioBridge® as an adjunct to microsurgical treatment April 14, 2021 – The University of Chicago Medicine has announced today that it is now enrolling patients into LymphBridge™, a randomized clinical study to evaluate a...
Multi-site clinical study to evaluate BioBridge® as prophylactic treatment for at-risk patients UNION CITY, Calif.--(BUSINESS WIRE)--Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced enrollment of the first...